NeOnc Technologies Secures $50 Million Investment from Quazar Investment

NeOnc Technologies Holdings, a biotech firm listed on NASDAQ, has finalized a strategic partnership with Quazar Investment, valuing $50 million. Key to this development is the incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM), marking crucial progress for NeOnc's expansion in the Middle East and North Africa (MENA) region.

This partnership aims to expedite the development of innovative therapies like NEO212 and NEO100, targeting brain cancer and central nervous system disorders. Amir Heshmatpour, Executive Chairman of NeOnc, stressed that this deal is vital for fulfilling their commitment to advancing life-saving treatments in a region needing medical innovation.

Waleed K. Al Ali, CEO of Quazar Investment, expressed pride in collaborating with NeOnc to enhance the biotech landscape in the UAE and broader regions. This collaboration highlights a significant step in transforming CNS treatment frameworks.

NeOnc's association with New to The Street ensures broad exposure, utilizing major platforms like Bloomberg and FOX Business to enhance visibility and reach regarding such strategic ventures.